Atopic Dermatitis

New atopic dermatitis treatment developments earn “hot topic” status at AAD.

The development of new biologics targeting a variety of dermatoses is on the upswing with some treatments coming to the clinic as early as this year, according to April Armstrong, M.D. who discussed the topic at the American Academy of Dermatology Spring Meeting in Washington, D.C.

Dr. Lawrence Eichenfield discusses a better understanding of disease pathogenesis, available therapies and proactive treatment approach improves the outlook for managing atopic dermatitis.

Dr. Jonathan Silverberg offers tips at AAD 2019 for diagnosing and managing atopic dermatitis in adults.

Healthcare disparities exist in all fields of medicine, including dermatology. We seek to address these disparities in this article by outlining the differences in epidemiology, presentation, access and outcomes of five conditions in patients with skin of color.

The FDA has reversed a long-standing guidance stating that sponsors of clinical trials for atopic dermatitis (AD) in pediatrics need not start the trial in adults first. Here's what you need to know.

Asana BioSciences announced that the U.S. Food and Drug Administration granted fast-track designation for the investigational ASN002, an oral treatment for moderate-to-severe atopic dermatitis. Learn more in this article.

The National Psoriasis Foundation and the National Eczema Association have awarded Procter & Gamble’s Tide Free and Gentle Liquid Laundry Detergent and Tide PODS Free and Gentle Laundry Detergent a “Seal of Recognition” and “Seal of Acceptance” for people with eczema or sensitive skin.

Before 2018 comes to a close, we wanted to say thank you to our readers from everyone here at Dermatology Times. As a thank you, we have compiled a list of the topics and issues you found most compelling throughout the year. Enjoy this slideshow - and see you in 2019!

Patients with moderate-to-severe atopic dermatitis are at high risk of having inadequate disease control, according to a cross-sectional study in JAMA Dermatology.

A 13-year-old girl presented with a history of atopic dermatitis and alopecia totalis. Nine months after starting dupilumab, the patient regrew hair on 60 percent of her scalp.

Severe case of dupilumab-associated conjunctivitis successfully managed without discontinuing therapy.

In this article, Dr. Peter A. Lio discusses how recent advances in atopic dermatitis have led to a new standard of care, which aims to keep patients clear safely and maximize improvements in quality of life.

Adults with severe and mostly active atopic eczema are at a higher risk of developing cardiovascular disease, a population-based study shows.

Physicians bypass systemic treatments in moderate to severe cases of atopic dermatitis despite its potential to control symptoms.

Cosmetic products with prebiotics, probiotics and postbiotics may be beneficial in treating eczema, a physician reported at the Fall Clinical Dermatology Conference held earlier this month in Las Vegas.

Dupilumab-associated conjunctivitis may warrant discontinuing therapy for atopic dermatitis, a study shows.

Atopic dermatitis patients are likely more willing to adhere to treatment and achieve better outcomes when there is shared decision-making between the clinician and patient, according to an article in press in the Annals of Allergy, Asthma and Immunology.

Combination treatment of dupilumab and topical corticosteroid treatment improved itch, mood and quality of life in adult patients with moderate-to-severe atopic dermatitis, according to a new trial.

Multiple burning, painful skin lesions appear on the legs the morning after a walk in the woods. What’s your diagnosis?

A study presented at EADV in Paris today showed that dupilumab met its primary endpoints in a phase three study of adolescents with moderate-to-severe atopic dermatitis.

In this slideshow, we highlight some of the most innovative and important clinical advances in the treatment of atopic dermatitis.

The biologic dupilumab is projected to be a cost-effective treatment for moderate-to-severe atopic dermatitis, shows a new study.  (©Dzm1try/Shutterstock.com)

Topical vitamin A provides no benefit in treating atopic dermatitis, whereas topical vitamin D may actually exacerbate symptoms, according to an evidence-based review.

A summary of treatments for atopic dermatitis in children.